
Johanna Kaufmann
Chief scientific officer of Deck Bio, a Massachusetts start-up developing T-cell engagers for solid tumours.
Last refreshed: 14 November 2026
Why have T-cell receptor drugs been so hard to make at scale?
Timeline for Johanna Kaufmann
T-Therapeutics raises $133m in Series B
UK Startups and InnovationBackground
Johanna Kaufmann is chief scientific officer of Deck Bio, an early-stage company in Cambridge, Massachusetts, working on T-cell engagers for solid tumours. She was previously executive vice president of oncology and immunology at Codagenix, and worked on immuno-oncology at GSK after its purchase of Tesaro.
She holds a PhD in cancer virology from the German Cancer Research Center and Heidelberg University.
As T-Therapeutics raised $133m in November 2026 for two T-cell receptor drugs, Kaufmann told BioPharm International that soluble T-cell receptor drugs have "historically" suffered from low manufacturing yields and poor stability. Each such receptor also works only in patients with a matching tissue type, which narrows the market for any one drug.
Who is Johanna Kaufmann of Deck Bio?
What are the problems with soluble T-cell receptor drugs?
What does Deck Bio do?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.